It's a big day for Moderna — and the world — as the FDA stamps an EUA on their vaccine. And there are some important lessons to remember
The FDA came through with an emergency authorization for Moderna’s mRNA vaccine for Covid-19 late Friday, in keeping with the fast delivery expected from regulators following a unanimous panel vote in its favor Thursday.
The approval has the greatest impact in the US, where Moderna is expected to rapidly start rolling out tens of millions of doses, even as a bitter wrangle develops over what is happening with Pfizer/BioNTech’s supply chain. In this case, unlike Pfizer, the biotech is marketing its very first product. Now, it has to literally deliver on schedule, while facing the same kind of skepticism that greeted the 10-year-old development revolutionary when they set out to build a pipeline.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.